Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Lymphoma, B-Cell 2Liver Neoplasms 2Hematologic Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Metastatic Solid Tumors 1Mesothelioma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hemorrhage 1Hematologic Diseases 1Head and Neck Neoplasms 1Gynecological Solid Tumors 1Fallopian Tube Neoplasms 1Erectile Dysfunction 1Diarrhea 1Colitis 1Childhood Solid Tumor 1Carcinoma, Hepatocellular 1

Interventions

Brentuximab Vedotin 21Cyclophosphamide 20fludarabine 16Rituximab 13Lenalidomide 13Dexamethasone 12fludarabine phosphate 10Melphalan 10Busulfan 10Mycophenolic Acid 9pirtobrutinib 7dacetuzumab 7Whole-Body Irradiation 7Tacrolimus 7Bortezomib 7Doxorubicin 6Azacitidine 6ruxolitinib 5Vincristine 5Prednisone 5Imatinib Mesylate 5Bone Marrow Transplantation 5ponatinib 4pomalidomide 4Mesna 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Blood Specimen Collection 4Bendamustine Hydrochloride 4venetoclax 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Cell- and Tissue-Based Therapy × Clear all
NCT06849921 2025-02-27

Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

Ruijin Hospital

Phase NA Active not recruiting
200 enrolled
Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡